Neurotrope Inc logo

NTRP - Neurotrope Inc Share Price

$0.941 0.0  0.0%

Last Trade - 01/12/20

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 7245
Unlock NTRP Revenue
Relative Strength (%)
1m -8.20%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020,Neurotrope Inc revenues was not reported. Net lossdecreased 22% to $9.7M. Lower net loss reflects Researchand development decrease of 76% to $1M (expense),Stock-based compensation decrease of 55% to $1.4M (expense), Stock-based compensation - related party decrease of 88%to $21K (expense). Basic Earnings per Share excludingExtraordinary Items increased from -$0.97 to -$0.45.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


NTRP Revenue Unlock NTRP Revenue

Net Income

NTRP Net Income Unlock NTRP Revenue

Normalised EPS

NTRP Normalised EPS Unlock NTRP Revenue

PE Ratio Range

NTRP PE Ratio Range Unlock NTRP Revenue

Dividend Yield Range

NTRP Dividend Yield Range Unlock NTRP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NTRP EPS Forecasts Unlock NTRP Revenue
Profile Summary

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 13, 2013
Public Since March 29, 2017
No. of Shareholders: 230
No. of Employees: 5
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange NASDAQ Capital Market
Shares in Issue 23,790,667
Free Float (0.0%)
Eligible for
NTRP Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NTRP
Upcoming Events for NTRP
Frequently Asked Questions for Neurotrope Inc
What is the Neurotrope Inc share price?

As of 01/12/20, shares in Neurotrope Inc are trading at $0.941, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Neurotrope Inc share price performed this year?

Shares in Neurotrope Inc are currently trading at $0.941 and the price has moved by 3.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neurotrope Inc price has moved by -20.54% over the past year.

What are the analyst and broker recommendations for Neurotrope Inc?

Of the analysts with advisory recommendations for Neurotrope Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neurotrope Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Neurotrope Inc next release its financial results?

Neurotrope Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Neurotrope Inc dividend yield?

Neurotrope Inc does not currently pay a dividend.

Does Neurotrope Inc pay a dividend?

Neurotrope Inc does not currently pay a dividend.

When does Neurotrope Inc next pay dividends?

Neurotrope Inc does not currently pay a dividend.

How do I buy Neurotrope Inc shares?

To buy shares in Neurotrope Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Neurotrope Inc?

Shares in Neurotrope Inc are currently trading at $0.941, giving the company a market capitalisation of £n/a.

Where are Neurotrope Inc shares listed? Where are Neurotrope Inc shares listed?

Here are the trading details for Neurotrope Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: NTRP
What kind of share is Neurotrope Inc?

We were not able to load our ranking data for Neurotrope Inc

Is there a Neurotrope Inc share price forecast 2021?

We were not able to load any forecast data for Neurotrope Inc.

How can I tell whether the Neurotrope Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurotrope Inc. Over the past six months, the relative strength of its shares against the market has been -40.8%. At the current price of $0.941, shares in Neurotrope Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Neurotrope Inc PE Ratio?

We were not able to find PE ratio data for Neurotrope Inc.

Who are the key directors of Neurotrope Inc?

We were unable to find the directors for Neurotrope Inc.

Who are the major shareholders of Neurotrope Inc?

Here are the top five shareholders of Neurotrope Inc based on the size of their shareholding:

Haywood (George W) Individual Investor
Percentage owned: 4.31% (1.03m shares)
McGregor (Clyde S) Individual Investor
Percentage owned: 4.29% (1.02m shares)
Intracoastal Capital, L.L.C. Corporation
Percentage owned: 2.76% (657k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.43% (341k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 1.42% (338k shares)
Similar to NTRP
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.